Abbott/FDA meeting
Executive Summary
On March 22, company execs met with Commissioner Young, CDER Director Carl Peck, MD, and CBER Director Paul Parkman, MD, to discuss Abbott's research with AIDS treatments and the approval process for drugs for life-threatening diseases. In its AIDS work, Abbott has reportedly been pursuing mapping projects similar to the Merck project publicized earlier this year. Discussion also included Abbott's research on AIDS diagnostics, including the review of the firm's HIV Antigen test, which was recommended for approval by FDA's Blood Products Advisory Committee on March 23 for diagnostic and prognostic use with AIDS patients.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.